Repligen Corporation $RGEN Shares Purchased by Geneva Capital Management LLC

Geneva Capital Management LLC raised its holdings in shares of Repligen Corporation (NASDAQ:RGEN) by 22.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 596,768 shares of the biotechnology company’s stock after purchasing an additional 109,234 shares during the period. Repligen comprises about 1.4% of Geneva Capital Management LLC’s portfolio, making the stock its 23rd largest holding. Geneva Capital Management LLC owned approximately 1.06% of Repligen worth $79,770,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. CWM LLC grew its position in shares of Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 135 shares during the last quarter. Trust Co. of Vermont bought a new position in shares of Repligen during the third quarter valued at approximately $67,000. Wilmington Savings Fund Society FSB grew its holdings in shares of Repligen by 2,750.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 495 shares during the last quarter. Hantz Financial Services Inc. raised its position in shares of Repligen by 92.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 586 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 282 shares during the period. Finally, UMB Bank n.a. lifted its holdings in shares of Repligen by 17.0% in the 3rd quarter. UMB Bank n.a. now owns 666 shares of the biotechnology company’s stock worth $89,000 after purchasing an additional 97 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RGEN. Barclays reduced their price objective on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Wells Fargo & Company cut their target price on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 25th. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. KeyCorp restated an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Finally, UBS Group cut their price objective on shares of Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $174.58.

Repligen Trading Down 4.8%

Shares of RGEN stock opened at $121.79 on Wednesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.12 and a current ratio of 8.37. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $175.77. The stock has a fifty day moving average of $148.33 and a two-hundred day moving average of $147.14. The firm has a market capitalization of $6.86 billion, a PE ratio of 143.28, a price-to-earnings-growth ratio of 2.49 and a beta of 1.14.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. Repligen had a return on equity of 4.71% and a net margin of 6.62%.The company’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same period last year, the company earned $0.44 earnings per share. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. As a group, research analysts expect that Repligen Corporation will post 1.72 EPS for the current year.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total transaction of $44,275.00. Following the transaction, the director owned 91,821 shares of the company’s stock, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.